Management of Spironolactone and Testosterone Replacement Therapy

Introduction to Combined Therapy

• The American College of Cardiology recommends continuing spironolactone in patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with mildly reduced ejection fraction (HFmrEF) who are undergoing testosterone replacement therapy (TRT), as the mortality benefit outweighs hormonal interaction concerns 3, 4.

Cardiovascular Considerations

• The American Heart Association suggests that spironolactone dosing should not exceed 25-50 mg daily for heart failure patients, as higher doses increase the risk of hyperkalemia 5.
• For patients with heart failure, spironolactone reduces cardiovascular death and hospitalization, and should be maintained 3, 4.

Monitoring Requirements

• The American College of Cardiology recommends checking potassium and renal function within 3 days of initiating either medication, rechecking at 1 week, then monthly for 3 months, then every 3 months 1, 2, 6.
• Testosterone replacement therapy monitoring should include PSA, hematocrit, and digital rectal examination at baseline, with follow-up at 1-2 months, then every 3-6 months for the first year, then yearly 7.

Safety Considerations

• The American Heart Association warns that patients on both medications require intensified potassium monitoring due to spironolactone's potassium-sparing effects, particularly if also taking ACE inhibitors or ARBs 1, 2, 5.
• Potassium levels >5.5 mEq/L require dose reduction or discontinuation of spironolactone, not adjustment of TRT 1, 2, 5.

Practical Management

• The American College of Cardiology suggests using the lowest effective dose (12.5-25 mg daily) of spironolactone to minimize both hyperkalemia risk and antiandrogenic effects 1, 2, 5.
• Baseline labs should include testosterone, PSA, hematocrit, potassium, and creatinine 7, 6.
• Target mid-to-upper normal testosterone range to overcome potential spironolactone interference 7.